Halozyme Therapeutics, Inc. (HALO)
Free
No email, no account, no signup.
Pulling latest news for Halozyme Therapeutics, Inc.…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceutical technology and royalties
Market Cap
$7.9B
Market sentiment
Sentiment has improved following an earnings beat and a larger-than-expected buyback program; overall newsflow is positive and focused on royalty growth and an expanding partner catalyst set.
Why BUY ?
Strong Q1 execution, reiterated 2026 guidance, and a sizable buyback program improve the near-term return profile and can support EPS/share price, while multiple partner-driven catalysts broaden the future royalty base.
- Consider adding incrementally (e.g., 2–3 tranches) given buyback support and upcoming partner/pipeline events, while staying prepared for partner-news-driven volatility.
We're already tracking Halozyme Therapeutics, Inc. — here are the latest events we've registered
Recent News
- On May 11, 2026 Halozyme reported Q1 2026 results with total revenue of $376.7M (+42% YoY) and royalty revenue of $240.7M (+43%), and reiterated full-year guidance. The company also announced a new share repurchase authorization of up to $1B (at least $400M to be repurchased during 2026). The period also featured partner/platform catalysts (e.g., the GSK ENHANZE oncology/ADC deal, Oruka/Hypercon, and positive partner data/label expansions).
Want to know how this news affects Halozyme Therapeutics, Inc.? Order the analysis.
Order analysis – Catalysts
31 Dec 2026 — Share repurchases: at least $400M during 2026
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Halozyme Therapeutics, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.